Rabbit Polyclonal BIM(Ab-69) Antibody

The BIM (BCL-2 Interacting Mediator of cell death) protein, encoded by the *BCL2L11* gene, is a pro-apoptotic member of the BCL-2 family that regulates mitochondrial apoptosis by neutralizing anti-apoptotic proteins like BCL-2 and MCL-1. Dysregulation of BIM is implicated in cancer progression, autoimmune disorders, and resistance to targeted therapies. The BIM(Ab-69) antibody is a monoclonal antibody specifically developed to detect distinct isoforms or post-translational modifications of the BIM protein. It is frequently utilized in research to study cell death mechanisms, particularly in contexts where BIM expression or stability is modulated by signaling pathways (e.g., MAPK/ERK or PI3K/AKT). This antibody is commonly applied in techniques such as Western blotting, immunohistochemistry, and flow cytometry to assess BIM protein levels, subcellular localization, or interactions in various cell types. Its specificity for particular BIM epitopes helps distinguish between isoforms (e.g., BIM-EL, BIM-L, BIM-S) or phosphorylation states, which are critical for understanding how survival signals or therapeutic agents influence apoptotic sensitivity. Studies employing BIM(Ab-69) have contributed to insights into cancer drug resistance, immune cell homeostasis, and neurodegenerative diseases, where BIM dysregulation plays a pathophysiological role.